Aurobindo Pharma receives 10 observations for Unit IX
Drug Approval

Aurobindo Pharma receives 10 observations for Unit IX

The company had responded to the agency and carried out the required corrective actions.

  • By IPP Bureau | November 21, 2022

The United States Food and Drug Administration (US FDA) inspected the Company's Unit - IX, an intermediate facility situated at Gundlamachnoor Village, Sangareddy District, Telangana, from November 10 to November 18, 2022.

The said Unit had been classified as OAI on May 17, 2019 and the company had responded to the agency and carried out the required corrective actions. The US FDA Authorities have reinspected the facility as mentioned above.

At the end of the inspection, the Company has been issued a 'Form 483' with 10 observations. In our view, these observations are procedural in nature and not related to data integrity. The Company will respond to the US FDA, within the stipulated timeline and shall work closely with the agency to address the observations at the earliest.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International